CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 83 enrolled
Drug / intervention
Oxytocin (OT) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03878589
NCT03878589Phase 3Completed

Mechanisms Underlying Oxytocin's Analgesia in Older Adults

University of Florida·interventional·Posted Mar 18, 2019·Updated Feb 23, 2026

In Brief

A Phase 3 clinical trial evaluating Oxytocin (OT) and Placebo (P) for Knee Osteoarthritis and Osteoarthritis. Completed, enrolled 83 participants across 2 sites.

Detailed Summary

Osteoarthritis (OA) represents a significant cause of disability worldwide and the knee is the most commonly affected joint. Oxytocin (OT) is a mediator of endogenous analgesia in animal and human studies. This proposal will test the efficacy and safety of self-administered intranasal OT over 4-weeks in older individuals relative to placebo (P) evaluating its effects on pain and function in aging and testing potential underlying neurobiological mechanisms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedMar 18, 2019
Enrollment StartAug 6, 2019
Primary CompletionDec 19, 2024
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 7.3 years ago

Interventions

Oxytocin (OT)drug

During the 4 week intervention, participants will self-administer twice daily 24 International Units intranasal oxytocin (OT) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.

Placebo (P)drug

During the 4 week intervention, participants will self-administer twice daily 24 International Units intranasal placebo (P) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.